Repositioning Candidate Details
| Candidate ID: | R0744 |
| Source ID: | DB05224 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | REP8839 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003). |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | For the treatment of bacterial infections caused by susceptible microorganisms (<i>Staphylococcus aureus</i>, including methicillin-resistant <i>S. aureus</i> (MRSA), and <i>Streptococcus pyogenes</i>). |
| DrugBank Pharmacology: | REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor with potent antibacterial activity against clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, and other clinically important gram-positive bacteria but little activity against gram-negative bacteria. |
| DrugBank MoA: | REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target. |
| Targets: | Methionine--tRNA ligase |
| Inclusion Criteria: | Indication associated |
